Clinical development of novel therapeutics for castration-resistant prostate cancer: Historic Challenges and Recent Successes

CA Cancer Journal for Clinicians

Volumn 62, Issue 5, 2012, Pages 299-308

  Galsky, Matthew D ^a   Small, Alexander C ^a   Tsao, Che Kai ^a   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN RECEPTOR; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CABOZANTINIB; CANCER VACCINE; CORTICOSTEROID; DENOSUMAB; DOCETAXEL; EPLERENONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PYROPHOSPHORIC ACID DERIVATIVE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; SUNITINIB; TAXANE DERIVATIVE; VINCA ALKALOID; ZOLEDRONIC ACID;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FRACTURE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; IMMUNOSTIMULATION; JAW OSTEONECROSIS; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEIZURE; SIDE EFFECT; SPINAL CORD COMPRESSION; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TUMOR FLARE; TUMOR GROWTH;

ANDROSTENOLS; ANILIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CASTRATION; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIDINES; RADIOPHARMACEUTICALS; RADIUM; RANK LIGAND; RECEPTOR PROTEIN-TYROSINE KINASES; TAXOIDS; TISSUE EXTRACTS;

EID: 84866353706     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21141     Document Type: Review

References (75)

1. Yagoda A, Petrylak D,. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71 (suppl 3): 1098-1109.
2. Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 1994; 12: 689-694.
3. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 2506-2513.
4. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756-1764.
5. Scher HI, Kelly WM, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999; 91: 244-251.
6. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD,. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 607-615.
7. Ferro MA, Gillatt D, Symes MO, Smith PJ,. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology. 1989; 34: 134-138.
8. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T,. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992; 147 (3 pt 2): 931-934.
9. Smith DC, Dunn RL, Strawderman MS, Pienta KJ,. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998; 16: 1835-1843.
10. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ,. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol. 1995; 13: 2944-2953.
11. Vollmer RT, Dawson NA, Vogelzang NJ,. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer. 1998; 83: 1989-1994.
12. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467.
13. Athanasiadis A, Tsavdaridis D, Rigatos SK, Athanasiadis I, Pergantas N, Stathopoulos GP,. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination. Anticancer Res. 2003; 23: 3085-3088.
14. Berry W, Dakhil S, Gregurich MA, Asmar L,. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001; 28 (4 suppl 15): 8-15.
15. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15: 3156-3163.
16. Petrylak DP, Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol. 1999; 26 (5 suppl 17): 28-33.
17. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001; 19: 2509-2516.
18. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA,. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002; 94: 1457-1465.
19. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
20. Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
21. Verbel DA, Heller G, Kelly WK, Scher HI,. Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res. 2002; 8: 2576-2579.
22. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI,; TAX-327 Investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008; 14: 2763-2767.
23. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006; 98: 516-521.
24. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431-440.
25. Galsky M, Kelly WK,. The development of differentiation agents for the treatment of prostate cancer. Semin Oncol. 2003; 30: 689-697.
26. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009; 20: 913-920.
27. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458-1468.
28. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Phamacol Exp Ther. 1996; 276: 473-481.
29. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1: 944-949.
30. Carducci MA, Saad F, Abrahamsson PA, et al. Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007; 110: 1959-1966.
31. Scher HI, Halabi S, Tannock I, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
32. Ryan CJ, Tindall DJ,. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011; 29: 3651-3658.
33. Scher HI, Morris MJ, Basch E, Heller G,. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011; 29: 3695-3704.
34. Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND,. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol. 2012; 61: 639-647.
35. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-3679.
36. Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
37. Huber ML, Haynes L, Parker C, Iversen P,. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104: 273-279.
38. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 1099-1105.
39. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009; 15: 723-730.
40. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM,. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39: 361-398.
41. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM,. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol. 2003; 138: 1367-1375.
42. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.
43. Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987; 13: 41-49.
44. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003; 9: 2587-2597.
45. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET,. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 2003; 63: 7883-7890.
46. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A, Cortes-Funes H,. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011; 16: 136-145.
47. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-822.
48. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012; 30: 637-643.
49. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26: 4563-4571.
50. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 1496-1501.
51. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28: 1489-1495.
52. de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
53. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001; 61: 3550-3555.
54. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10: 33-39.
55. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324: 787-790.
56. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/ Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375: 1437-1446.
57. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study [abstract]. J Clin Oncol. 2012; 30 (suppl 5). Abstract LBA1.
58. Sartor O,. Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr Oncol Rep. 2003; 5: 258-262.
59. Tu SM, Lin SH, Podoloff DA, Logothetis CJ,. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010; 8: 341-351.
60. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001; 357: 336-341.
61. Liepe K,. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009; 10: 1346-1358.
62. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007; 8: 587-594.
63. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (apharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Presented at: European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 1LBA. http://www.algeta.com. Accessed January 17, 2012.
64. George DJ, Halabi S, Shepard TF, et al. Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001; 7: 1932-1936.
65. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract]. ASCO Meeting Abstracts. 2010; 28: LBA4511.
66. Ou Y, Michaelson MD, Sengelov L, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU + P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]. ASCO Meeting Abstracts. 2011; 29: 4515.
67. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z,. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007; 67: 967-975.
68. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF,. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 2008; 14: 7385-7390.
69. Hurle RA, Davies G, Parr C, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 2005; 20: 1339-1349.
70. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995; 147: 386-396.
71. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]. ASCO Meeting Abstracts. 2011; 29: 4516.
72. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011; 29: 2191-2198.
73. Small EJ, Demkov T, Gerritsen W, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. In: 2009 Genitourinary (GU) Cancers Symposium; February 26-28, 2009; Orlando, FL. Abstract 7.
74. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011; 19: 575-586.
75. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011; 19: 792-804.